Autolus Therapeutics PLC $ 15.03 0.34 (2.31%)
Volume:
312,386
Avg Vol (1m):
241,666
Market Cap $:
785.26 Mil
Enterprise Value $:
568.61 Mil
P/E (TTM):
0.00
P/B:
2.72
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 9.13 | ||
| Equity-to-Asset | 0.85 | ||
| Debt-to-Equity | 0.09 | ||
| Debt-to-EBITDA | -0.18 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 7.59 | ||
| Beneish M-Score | -3.74 | ||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -11729.02 | ||
| Net Margin % | -9870.75 | ||
| ROE % | -47.64 | ||
| ROA % | -40.39 | ||
| ROC (Joel Greenblatt) % | -288.65 | ||
| 3-Year Revenue Growth Rate | -8.2 | ||
| 3-Year EBITDA Growth Rate | -46.8 | ||
| 3-Year EPS without NRI Growth Rate | -115.9 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 2.72 | ||
| PS Ratio | 518.28 | ||
| EV-to-EBIT | -3.81 | ||
| EV-to-EBITDA | -3.88 | ||
| EV-to-Revenue | 443.53 | ||
| Current Ratio | 10.78 | ||
| Quick Ratio | 10.78 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -48.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.73 | ||
| Earnings Yield (Greenblatt) % | -26.45 |